Dr. Mali's Top 5 Predictions in Ophthalmology for 2022

<p>In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.</p> <ul> <li>Welcome to another exciting episode of Eye Care insider <strong><em>:50</em></strong></li> <li>My top 5 predictions for 2022 <strong><em>1:16</em></strong></li> <li>Prediction #1 – on COVID-19 <strong><em>1:27</em></strong></li> <li>Prediction #2 – on wet AMD <strong><em>2:43</em></strong></li> <li>Prediction #3 – on ocular gene therapy <strong><em>4:05</em></strong></li> <li>Prediction #4 – on geographic atrophy <strong><em>5:05</em></strong></li> <li>Prediction #5 – on ophthalmology media platforms <strong><em>7:23</em></strong></li> <li>Thanks for listening <strong><em>9:20</em></strong></li> </ul> <p>We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can contact Mogan by going to the company’s website, <a href= "http://www.parkplacepayments.com">www.parkplacepayments.com</a> or at <a href= "https://www.linkedin.com/in/jennifer-mogan-97b75a1b0">Linkedin</a>.</p> <p><strong>Disclosures:</strong> Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.</p>